Experienced in Cerebrospinal Fluid Leak

Dr. Nader Sanai

Phoenix, AZ
Experienced
in Cerebrospinal Fluid Leak
Specialties:Neurosurgery
OverviewInsuranceLocationsClinical Research

Overview

Nader Sanai is a Neurosurgery provider in Phoenix, Arizona. Dr. Sanai and is rated as an Experienced provider by MediFind in the treatment of Cerebrospinal Fluid Leak. His top areas of expertise are Glioblastoma, Glioma, Brain Tumor, Awake Craniotomy, and Gastrostomy.

His clinical research consists of co-authoring 134 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Licenses
Neurological Surgery in AZ
Hospital Affiliations
Yuma Regional Medical Center
St. Joseph's Hospital And Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

NEUROSURGICAL ASSOCIATES LTD
2910 N 3rd Ave, Suite 200, Phoenix, AZ 85013
602-406-3181

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 0 'trigger' Trial of Niraparib in Newly-diagnosed Glioblastoma and Recurrent IDH1/2(+) ATRX Mutant Glioma
A Phase 0 'trigger' Trial of Niraparib in Newly-diagnosed Glioblastoma and Recurrent IDH1/2(+) ATRX Mutant Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Radiation, Drug
Study Drug: Niraparib
Study Phase: Early Phase 1
A Phase 2 Dose-escalation Study Examining the Safety, Pharmacokinetics, and Preliminary Efficacy of Ascending Drug and Energy Dose Combinations for Sonodynamic Therapy Using SONALA-001 in Combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in Subjects with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
A Phase 2 Dose-escalation Study Examining the Safety, Pharmacokinetics, and Preliminary Efficacy of Ascending Drug and Energy Dose Combinations for Sonodynamic Therapy Using SONALA-001 in Combination with Exablate 4000 Type 2.0 MR-Guided Focused Ultrasound in Subjects with Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
Enrollment Status: Suspended
Publish Date: September 19, 2024
Intervention Type: Combination product
Study Drug: SONALA-001+MR-Guided Focused Ultrasound device
Study Phase: Phase 2
A Phase 0/II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Rb-Intact Recurrent High-Grade Glioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
A Phase 0/II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Rb-Intact Recurrent High-Grade Glioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Enrollment Status: Completed
Publish Date: August 05, 2024
Intervention Type: Drug
Study Drugs: Ribociclib, Everolimus
Study Phase: Early Phase 1
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2024
Intervention Type: Radiation, Procedure, Drug
Study Drug: Temozolomide
Study Phase: Phase 3
A Phase 0 Study of Infigratinib in Recurrent High-Grade Glioma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK Triggered Expansion Cohort
A Phase 0 Study of Infigratinib in Recurrent High-Grade Glioma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK Triggered Expansion Cohort
Enrollment Status: Terminated
Publish Date: March 27, 2024
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Early Phase 1
A Phase 0/II Study of Ribociclib (LEE011) in Preoperative Rb-Positive Recurrent High-Grade Glioma and Meningioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
A Phase 0/II Study of Ribociclib (LEE011) in Preoperative Rb-Positive Recurrent High-Grade Glioma and Meningioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Enrollment Status: Active_not_recruiting
Publish Date: March 27, 2024
Intervention Type: Drug
Study Drug: Ribociclib
Study Phase: Early Phase 1
Barrow 5-ALA Intraoperative Confocal Evaluation Trial
Barrow 5-ALA Intraoperative Confocal Evaluation Trial
Enrollment Status: Completed
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: 5-Aminolevulinic acid
Study Phase: Phase 3
A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Enrollment Status: Completed
Publish Date: December 11, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

132 Total Publications

A Hitchhiker's Guide Toward CSF Biomarkers for Neuro-Oncology.
A Hitchhiker's Guide Toward CSF Biomarkers for Neuro-Oncology.
Journal: Neuro-oncology
Published: November 05, 2024
Similar Doctors
Expertise in
72
conditions
Dr. Bernard Bendok
Neurosurgery
Expertise in
72
conditions
Dr. Bernard Bendok
Neurosurgery

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (17.8 mi)
480-301-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bernard Bendok is a Neurosurgery provider in Scottsdale, Arizona. Dr. Bendok and is rated as an Elite provider by MediFind in the treatment of Cerebrospinal Fluid Leak. His top areas of expertise are Brain Aneurysm, Arteriovenous Malformation, Cerebral Arteriovenous Malformation, Endovascular Embolization, and Balloon Sinuplasty.

Expertise in
10
conditions
Dr. Joshua Bakhsheshian
Neurosurgery | Orthopedics
Expertise in
10
conditions
Dr. Joshua Bakhsheshian
Neurosurgery | Orthopedics

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (17.8 mi)
480-301-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joshua Bakhsheshian is a Neurosurgery specialist and an Orthopedics provider in Scottsdale, Arizona. Dr. Bakhsheshian and is rated as an Advanced provider by MediFind in the treatment of Cerebrospinal Fluid Leak. His top areas of expertise are Lordosis, Cerebrospinal Fluid Leak, Tumefactive Multiple Sclerosis, Cerebral Artery Bypass Surgery, and Laminectomy.

Expertise in
50
conditions
Dr. Andrew S. Little
Neurosurgery
Expertise in
50
conditions
Dr. Andrew S. Little
Neurosurgery

Neurosurgical Associates Ltd

2910 N 3rd Ave, Suite 200, 
Phoenix, AZ 
602-406-3181
Languages Spoken:
English
Offers Telehealth

Andrew Little is a Neurosurgery provider in Phoenix, Arizona. Dr. Little and is rated as an Elite provider by MediFind in the treatment of Cerebrospinal Fluid Leak. His top areas of expertise are Pituitary Tumor, Hypothalamic Tumor, Brain Tumor, Endoscopic Transnasal Transsphenoidal Surgery, and Balloon Sinuplasty.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile